Targeting telomerase to overcome drug resistance in lung cancer treatment
Targeting hTERT/telomerase for managing acquired resistance to third generation EGFR-TKIs in lung cancer
This study is looking at how lung cancer cells become resistant to a treatment called osimertinib, and it aims to find new ways to make this treatment work better for patients by focusing on a protein that helps cancer cells grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11067825 on NIH RePORTER |
What this research studies
This research investigates how cancer cells develop resistance to a specific lung cancer treatment called osimertinib. It focuses on understanding the molecular mechanisms behind this resistance and aims to develop new strategies to counteract it. By targeting telomerase, a protein linked to cancer cell growth, the research seeks to improve treatment outcomes for patients with advanced lung cancer. Patients may benefit from new therapies that could enhance the effectiveness of existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with EGFR mutant non-small cell lung cancer (NSCLC) who have experienced treatment resistance.
Not a fit: Patients with lung cancer who do not have EGFR mutations or who have not undergone treatment with osimertinib may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting telomerase in cancer therapies, indicating potential for success in this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Sun, Shi-Yong — Emory University
- Study coordinator: Sun, Shi-Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.